We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Read MoreHide Full Article
Dr. Reddy’s Laboratories (RDY - Free Report) and partner, Alvotech (ALVO - Free Report) , announced the FDA’s acceptance of a regulatory filing, seeking the approval of AVT03, a proposed biosimilar of Amgen’s (AMGN - Free Report) Prolia (denosumab) and Xgeva (denosumab), for review.
The biologic license application (BLA) was submitted under the 351(k) pathway, which is the FDA’s biosimilar application process. AVT03 is a human monoclonal antibody developed by Alvotech.
Amgen's Prolia treats osteoporosis in postmenopausal women at high risk of fractures, especially when other treatments are ineffective. AMGN’s Xgeva helps prevent fractures, spinal cord compression and the need for bone-related surgery or radiation in patients with multiple myeloma or bone metastases from solid tumors.
Both drugs play a crucial role in Amgen’s revenue stream. In 2024, Prolia generated $2.89 billion in sales, reflecting an 8% year-over-year increase. Meanwhile, Xgeva brought in $1.51 billion, marking 5% growth compared with 2023.
Year to date, Dr. Reddy’s shares have lost 15.5% compared with the industry’s 16.4% decline.
Image Source: Zacks Investment Research
Subject to approval, RDY/ALVO’s AVT03 could significantly enhance patient access to affordable treatment options for osteoporosis and other bone-related conditions. AVT03’s approval would align with broader efforts to expand the availability of high-quality biologic medicines. Given the high cost of branded drugs, a biosimilar alternative could provide substantial financial relief to patients and healthcare systems.
Additionally, with osteoporosis affecting millions across the United States, the introduction of AVT03 could improve treatment accessibility for a large patient population in need of effective bone health therapies.
RDY’s Ongoing Partnership With Alvotech for AVT03
Dr. Reddy’s and Alvotech signed a license and supply agreement for AVT03 in 2024, outlining their respective roles in bringing the biosimilar to market. Per the agreement, Alvotech is responsible for the development and manufacturing of AVT03, while Dr. Reddy’s is tasked with its registration and commercialization in key markets, including the United States.
Year to date, Alvotech shares have lost 14.3% against the industry’s 7.4% growth.
Image Source: Zacks Investment Research
Contingent upon the FDA’s approval, AVT03 is expected to be available in two formulations, a single-dose prefilled syringe containing 60 mg in a 1 mL solution and a single-dose vial with 120 mg/1.7 mL (70 mg/mL) solution. RDY and ALVO have clarified that AVT03 is an investigational product that has not been approved by any regulatory authority. Its biosimilarity has also not been established or claimed.
RDY & ALVO’s Zacks Rank and Stock to Consider
Dr. Reddy’s and Alvotech carry a Zacks Rank #3 (Hold) each at present.
In the past 30 days, Gilead Sciences’ earnings estimate for 2025 has improved from $7.80 to $7.87 per share. During the same timeframe, the estimate for earnings per share for 2026 has improved from $8.12 to $8.27. Year to date, shares of Gilead Sciences have gained 16.1%.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Dr. Reddy’s Laboratories (RDY - Free Report) and partner, Alvotech (ALVO - Free Report) , announced the FDA’s acceptance of a regulatory filing, seeking the approval of AVT03, a proposed biosimilar of Amgen’s (AMGN - Free Report) Prolia (denosumab) and Xgeva (denosumab), for review.
The biologic license application (BLA) was submitted under the 351(k) pathway, which is the FDA’s biosimilar application process. AVT03 is a human monoclonal antibody developed by Alvotech.
Amgen's Prolia treats osteoporosis in postmenopausal women at high risk of fractures, especially when other treatments are ineffective. AMGN’s Xgeva helps prevent fractures, spinal cord compression and the need for bone-related surgery or radiation in patients with multiple myeloma or bone metastases from solid tumors.
Both drugs play a crucial role in Amgen’s revenue stream. In 2024, Prolia generated $2.89 billion in sales, reflecting an 8% year-over-year increase. Meanwhile, Xgeva brought in $1.51 billion, marking 5% growth compared with 2023.
Year to date, Dr. Reddy’s shares have lost 15.5% compared with the industry’s 16.4% decline.
Image Source: Zacks Investment Research
Subject to approval, RDY/ALVO’s AVT03 could significantly enhance patient access to affordable treatment options for osteoporosis and other bone-related conditions. AVT03’s approval would align with broader efforts to expand the availability of high-quality biologic medicines. Given the high cost of branded drugs, a biosimilar alternative could provide substantial financial relief to patients and healthcare systems.
Additionally, with osteoporosis affecting millions across the United States, the introduction of AVT03 could improve treatment accessibility for a large patient population in need of effective bone health therapies.
RDY’s Ongoing Partnership With Alvotech for AVT03
Dr. Reddy’s and Alvotech signed a license and supply agreement for AVT03 in 2024, outlining their respective roles in bringing the biosimilar to market. Per the agreement, Alvotech is responsible for the development and manufacturing of AVT03, while Dr. Reddy’s is tasked with its registration and commercialization in key markets, including the United States.
Year to date, Alvotech shares have lost 14.3% against the industry’s 7.4% growth.
Image Source: Zacks Investment Research
Contingent upon the FDA’s approval, AVT03 is expected to be available in two formulations, a single-dose prefilled syringe containing 60 mg in a 1 mL solution and a single-dose vial with 120 mg/1.7 mL (70 mg/mL) solution. RDY and ALVO have clarified that AVT03 is an investigational product that has not been approved by any regulatory authority. Its biosimilarity has also not been established or claimed.
RDY & ALVO’s Zacks Rank and Stock to Consider
Dr. Reddy’s and Alvotech carry a Zacks Rank #3 (Hold) each at present.
A better-ranked stock from the sector is Gilead Sciences (GILD - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, Gilead Sciences’ earnings estimate for 2025 has improved from $7.80 to $7.87 per share. During the same timeframe, the estimate for earnings per share for 2026 has improved from $8.12 to $8.27. Year to date, shares of Gilead Sciences have gained 16.1%.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.